BRPI0905680A2 - "composição farmacêutica de uma composição farmacêutica" - Google Patents

"composição farmacêutica de uma composição farmacêutica"

Info

Publication number
BRPI0905680A2
BRPI0905680A2 BRPI0905680-7A BRPI0905680A BRPI0905680A2 BR PI0905680 A2 BRPI0905680 A2 BR PI0905680A2 BR PI0905680 A BRPI0905680 A BR PI0905680A BR PI0905680 A2 BRPI0905680 A2 BR PI0905680A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BRPI0905680-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Muhammad Safadi
Dannit Licht
Rachel Cohen
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BRPI0905680A2 publication Critical patent/BRPI0905680A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0905680-7A 2008-01-11 2009-01-09 "composição farmacêutica de uma composição farmacêutica" BRPI0905680A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1086008P 2008-01-11 2008-01-11
PCT/US2009/000134 WO2009089049A1 (en) 2008-01-11 2009-01-09 Rasagiline formulations, their preparation and use

Publications (1)

Publication Number Publication Date
BRPI0905680A2 true BRPI0905680A2 (pt) 2015-07-07

Family

ID=40850833

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0905680-7A BRPI0905680A2 (pt) 2008-01-11 2009-01-09 "composição farmacêutica de uma composição farmacêutica"

Country Status (15)

Country Link
US (1) US20090181086A1 (enExample)
EP (1) EP2234478A4 (enExample)
JP (2) JP5583597B2 (enExample)
KR (1) KR20100107028A (enExample)
CN (1) CN101909438A (enExample)
AU (1) AU2009204454B2 (enExample)
BR (1) BRPI0905680A2 (enExample)
CA (1) CA2711817A1 (enExample)
EA (1) EA201070842A1 (enExample)
IL (1) IL206136A0 (enExample)
MX (1) MX2010007601A (enExample)
NZ (1) NZ586025A (enExample)
SG (1) SG187455A1 (enExample)
WO (1) WO2009089049A1 (enExample)
ZA (1) ZA201004086B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2574925A1 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
ZA200704917B (en) * 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
CA2600011C (en) * 2005-02-23 2015-11-10 Teva Pharmaceutical Industries Ltd. Rasagiline formulations of improved content uniformity
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
US8946300B2 (en) 2006-04-03 2015-02-03 Teva Pharmaceutical Industries, Ltd. Use of rasagilline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
PT2101569E (pt) * 2006-12-14 2012-01-13 Teva Pharma Base de rasagilina sólida cristalina
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
US20100008983A1 (en) * 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
MX2010013766A (es) * 2008-06-13 2011-03-15 Teva Pharmaceutical Ind Ltd Star Rasagilina para modificacion de enfermedad de parkinson.
CA2727021A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
MX2010013875A (es) 2008-06-19 2011-01-20 Teva Pharma Proceso para preparar y secar base de rasagilina solida.
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
AU2010341499A1 (en) 2009-12-22 2012-08-09 Teva Pharmaceutical Industries Ltd. 3-keto-N-propargyl-1-aminoindan
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
WO2013055687A2 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
EP2766004A4 (en) 2011-10-10 2015-04-22 Teva Pharma R (+) - N-methyl-propargyl-aminoindan
BR112015003451A2 (pt) 2012-08-17 2017-07-04 Teva Pharma formulação parentérica de rasagilina
WO2024098098A1 (en) * 2022-11-07 2024-05-16 Natural MedTech Pty Ltd Tryptamine formulations and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
FI955979L (fi) * 1993-06-14 1995-12-13 Janssen Pharmaceutica Nv Jatkuvasti vapauttava, kalvopäällysteinen astemitsoli- ja pseudoefedriinitabletti
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
EP0966435B1 (en) * 1996-12-18 2005-04-06 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
SI1567152T1 (sl) * 2002-11-15 2013-10-30 Teva Pharmaceutical Industries Ltd. Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
US20050220864A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
CA2574925A1 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
EP1663167A1 (en) * 2004-07-26 2006-06-07 Teva Pharmaceutical Industries Ltd Dosage forms with an enterically coated core tablet
ZA200704917B (en) * 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
CA2600011C (en) * 2005-02-23 2015-11-10 Teva Pharmaceutical Industries Ltd. Rasagiline formulations of improved content uniformity
US7572834B1 (en) * 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
PT2101569E (pt) * 2006-12-14 2012-01-13 Teva Pharma Base de rasagilina sólida cristalina
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
US20100008983A1 (en) * 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
MX2010013766A (es) * 2008-06-13 2011-03-15 Teva Pharmaceutical Ind Ltd Star Rasagilina para modificacion de enfermedad de parkinson.
CA2727021A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
MX2010013875A (es) * 2008-06-19 2011-01-20 Teva Pharma Proceso para preparar y secar base de rasagilina solida.
EP2328861A2 (en) * 2008-07-11 2011-06-08 Synthon BV Polymorphs of rasagiline hydrochloride
US20100029987A1 (en) * 2008-07-29 2010-02-04 Dipharma Francis S.R.I. Crystalline Form of Rasagiline and Process for the Preparation Thereof
DE102008064061A1 (de) * 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
JP2013507352A (ja) * 2009-10-09 2013-03-04 テバ ファーマシューティカル インダストリーズ リミティド 進行性核上性麻痺の治療のためのラサギリンの使用
AU2010341499A1 (en) * 2009-12-22 2012-08-09 Teva Pharmaceutical Industries Ltd. 3-keto-N-propargyl-1-aminoindan
AU2011282716A1 (en) * 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
AU2011282720B2 (en) * 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
CN103188933A (zh) * 2010-10-26 2013-07-03 泰华制药工业有限公司 富集氘的雷沙吉兰
JP2014534195A (ja) * 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトルアミド
EP2766004A4 (en) * 2011-10-10 2015-04-22 Teva Pharma R (+) - N-methyl-propargyl-aminoindan
WO2013055687A2 (en) * 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan

Also Published As

Publication number Publication date
AU2009204454B2 (en) 2015-02-05
JP2011509295A (ja) 2011-03-24
EP2234478A1 (en) 2010-10-06
AU2009204454A1 (en) 2009-07-16
MX2010007601A (es) 2010-08-03
NZ586025A (en) 2012-08-31
US20090181086A1 (en) 2009-07-16
SG187455A1 (en) 2013-02-28
WO2009089049A1 (en) 2009-07-16
EP2234478A4 (en) 2013-01-23
EA201070842A1 (ru) 2011-04-29
IL206136A0 (en) 2010-11-30
CN101909438A (zh) 2010-12-08
KR20100107028A (ko) 2010-10-04
ZA201004086B (en) 2011-08-31
JP5583597B2 (ja) 2014-09-03
JP2014237668A (ja) 2014-12-18
CA2711817A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
BRPI0905680A2 (pt) "composição farmacêutica de uma composição farmacêutica"
LTPA2018014I1 (lt) Farmacinė kompozicija 514
LTPA2018005I1 (lt) Farmacinė kompozicija
BRPI0810928A2 (pt) "composição farmacêutica"
BRPI0721651A2 (pt) Composição farmacêutica
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
BRPI0715712A2 (pt) Composição farmacêutica
DK3492069T3 (da) Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
BRPI0821165A2 (pt) Uso de uma composição
BRPI0719393A2 (pt) Composição farmacêutica
EP2191826A4 (en) PHARMACEUTICAL COMPOSITION
DK2120884T3 (da) Farmaceutisk sammensætning
BRPI0720234A2 (pt) Composição farmacêutica
BRPI0716445A2 (pt) composiÇço farmacÊutica
DK2285413T3 (da) Farmaceutisk sammensætning
EP2236149A4 (en) MEDICAL COMPOSITION
BRPI0916069A2 (pt) "composto, usos de um composto, composição farmacêutica, composição cosmética e usos cosméticos de uma composição"
PT2209464E (pt) Composição farmacêutica antimalárica
BRPI0921313A2 (pt) composição farmaucêutica
BRPI1006666A2 (pt) " composição farmacêutica e uso de uma composição farmacêutica"
BRPI0820198A2 (pt) composições farmacêuticas
BRPI0912171A2 (pt) composição farmacêutica
DK2271321T3 (da) Farmaceutisk sammensætning 271
BRPI0909128A2 (pt) composição compreendendo uma mistura de resinas
EP2116241A4 (en) PHARMACEUTICAL COMPOSITION

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]